Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

72.7%

8 terminated/withdrawn out of 11 trials

Success Rate

11.1%

-75.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

500%

5 of 1 completed trials have results

Key Signals

2 recruiting5 with results7 terminated

Enrollment Performance

Analytics

Phase 1
7(63.6%)
Phase 2
4(36.4%)
11Total
Phase 1(7)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT02392572Phase 1Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Role: collaborator

NCT05542407Phase 1Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Role: collaborator

NCT03295396Phase 2Terminated

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Role: collaborator

NCT03416530Phase 1Terminated

ONC201 in Pediatric H3 K27M Gliomas

Role: collaborator

NCT03099499Phase 2Terminated

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Role: collaborator

NCT03485729Phase 2Terminated

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Role: collaborator

NCT02525692Phase 2Terminated

Oral ONC201 in Adult Recurrent Glioblastoma

Role: collaborator

NCT02863991Phase 1Terminated

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT03791398Phase 1Terminated

BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

Role: collaborator

NCT04854044Phase 1Withdrawn

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Role: collaborator

NCT02324621Phase 1Completed

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Role: collaborator

All 11 trials loaded